Temodex产品介绍

发布时间：2019-11-25

Temodex is an experimental medicine for treatment of brain cancers; Temodex is a formulation of temozolomide and a biodegradable polymer. Temodex was registered as a first line treatment of glioblastoma in Belarus 2014. EMA’s Orphan Drug status for Temodex was received in July 2016. European clinical trials are planned to be started during 2020. Temodex is a gel that is locally administered in the cavity formed after resection of brain tumours. Thereby it can start to act against remaining tumour cells immediately after the removal of the tumour. Temozolomide, the active pharmaceutical ingredient in Temodex, is an imidazotetrazine derivative of the alkylating agent dacarbazine and is for this reason a drug which is considered to be a prodrug. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. The therapeutic benefit of temozolomide is due to its ability to alkylate / methylate DNA. This alkylation / methylation destroys the DNA and triggers the death of the tumour cells. Temozolomide was developed by Malcolm Stevens and his team at Aston University in Birmingham in UK and has been available in the US since 1999, and in other countries since 2000.